Law

Using the Risk-Utility Analysis to Decide if the Absence of a Safety Feature Produced a Defective Product

When designing a product, a manufacturer has a duty to exercise care in selecting from among alternative product designs to reduce the foreseeable risks of harm presented in the use of the product.
ascopubs.org

Cost-Utility Analysis of Geriatric Assessment and Management in Older Adults With Cancer: Economic Evaluation Within 5C Trial

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial The economic evaluation, conducted from societal ...
JD Supra

Changing Trend: Risk-Utility May No Longer Be The Favored Test for Design Defect Claims

In the world of products liability, design defect claims arise when the product is inherently dangerous in its design. The test for whether a product is inherently dangerous has evolved in modern ...
CMAJ

Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer

Background: Apixaban (2.5 mg) taken twice daily has been shown to substantially reduce the risk of venous thromboembolism (VTE) compared with placebo for the primary thromboprophylaxis of ambulatory ...
ascopubs.org

A cost-utility analysis of atezolizumab in the second-line treatment of metastatic urothelial carcinoma.

Clinical benefit and prices of cancer drugs in the United States and Europe. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not include a full text component.